These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17476660)

  • 1. Selective growth of a stable drug polymorph by suppressing the nucleation of corresponding metastable polymorphs.
    Cox JR; Ferris LA; Thalladi VR
    Angew Chem Int Ed Engl; 2007; 46(23):4333-6. PubMed ID: 17476660
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitaxial 2D nucleation of the stable polymorphic form of the steroid 7alphaMNa on the metastable form: implications for Ostwald's rule of stages.
    Stoica C; Verwer P; Meekes H; Vlieg E; van Hoof PJ; Kaspersen FM
    Int J Pharm; 2006 Feb; 309(1-2):16-24. PubMed ID: 16384675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular simulation of cross-nucleation between polymorphs.
    Desgranges C; Delhommelle J
    J Phys Chem B; 2007 Feb; 111(6):1465-9. PubMed ID: 17243668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-nucleation between ROY polymorphs.
    Chen S; Xi H; Yu L
    J Am Chem Soc; 2005 Dec; 127(49):17439-44. PubMed ID: 16332095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface modification with orthogonal photosensitive silanes for sequential chemical lithography and site-selective particle deposition.
    del Campo A; Boos D; Spiess HW; Jonas U
    Angew Chem Int Ed Engl; 2005 Jul; 44(30):4707-12. PubMed ID: 15995990
    [No Abstract]   [Full Text] [Related]  

  • 8. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorph selection during the crystallization of Yukawa systems.
    Desgranges C; Delhommelle J
    J Chem Phys; 2007 Feb; 126(5):054501. PubMed ID: 17302479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the molecular mechanism underlying polymorph selection.
    Desgranges C; Delhommelle J
    J Am Chem Soc; 2006 Nov; 128(47):15104-5. PubMed ID: 17117858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of high-speed differential scanning calorimetry (Hyper-DSC) in the study of pharmaceutical polymorphs.
    McGregor C; Bines E
    Int J Pharm; 2008 Feb; 350(1-2):48-52. PubMed ID: 17890030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorph control: past, present and future.
    Llinàs A; Goodman JM
    Drug Discov Today; 2008 Mar; 13(5-6):198-210. PubMed ID: 18342795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism for the cross-nucleation between polymorphs.
    Desgranges C; Delhommelle J
    J Am Chem Soc; 2006 Aug; 128(32):10368-9. PubMed ID: 16895393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of cross-nucleation between polymorphs.
    Tao J; Yu L
    J Phys Chem B; 2006 Apr; 110(14):7098-101. PubMed ID: 16599470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances.
    Reutzel-Edens SM
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):806-15. PubMed ID: 17117688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surface-induced crystallization of pharmaceuticals and biopharmaceuticals: A review.
    Artusio F; Pisano R
    Int J Pharm; 2018 Aug; 547(1-2):190-208. PubMed ID: 29859921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation.
    Moribe K; Tozuka Y; Yamamoto K
    Adv Drug Deliv Rev; 2008 Feb; 60(3):328-38. PubMed ID: 18006109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of drug substance material properties in the processibility and performance of a wet granulated product.
    Vemavarapu C; Surapaneni M; Hussain M; Badawy S
    Int J Pharm; 2009 Jun; 374(1-2):96-105. PubMed ID: 19446765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorph formation studied by 3D nucleation simulations. Application to a yellow isoxazolone dye, paracetamol, and L-glutamic acid.
    Deij MA; ter Horst JH; Meekes H; Jansens P; Vlieg E
    J Phys Chem B; 2007 Feb; 111(7):1523-30. PubMed ID: 17266356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.